Retrovirology



Poster presentation

Open Access

Up-regulation of interferon-a/APOBEC3G signal pathway potently inactivates HIV-I infectivity in resting CD4-T cells

Keyang Chen, Jialing Huang, Chune Zhang, Sophia Huang, Giuseppe Nunnari, Feng-xiang Wang, Xiangrong Tong, Ling Gao, Kristi Nikisher and Hui Zhang*

Address: Center for Human Virology, Division of Infectious Diseases, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, USA

* Corresponding author

from 2006 International Meeting of The Institute of Human Virology Baltimore, USA. 17–21 November, 2006

Published: 21 December 2006

Retrovirology 2006, 3(Suppl 1):P69 doi:10.1186/1742-4690-3-S1-P69

© 2006 Chen et al; licensee BioMed Central Ltd.

Background

Interferon (IFN) system, including various IFNs and IFNinducible gene products, is well known for its potent innate immunity against wide-range viruses. Recently, a family of cytidine deaminases, functioning as another innate immunity against retroviral infection, has been identified. However, its regulation remains largely unknown.

Methods

IFN-a was added to the culture of resting CD4 T-cells. The expression of APOBEC3G was detected with real time RT-PCR and Western blotting. The promoter of APOBEC3G was analyzed by luciferase expression. The effect of IFN-a/APOBEC3G upon HIV-1 was examined by treating the cells with APOBEC3G-specific siRNA.

Results

We have demonstrated that, through a regular IFN-a signal transduction pathway, IFN-a can significantly enhance the expression of APOBEC3G in human primary resting but not activated CD4 T-cells, and the amounts of APOBEC3G associated with a low molecular mass (LMM). Interestingly, short-time treatments of newly-infected resting CD4 T-cells with IFN-a will significantly inactivate human immunodeficiency virus type 1 (HIV-1) at its early stage. This inhibition can be counteracted by APOBEC3G-specific short interfering RNA (siRNA), indi-

cating that IFN-a-induced APOBEC3G plays a key role to mediate this anti-HIV-1 process.

Conclusion

Our data suggest that APOBEC3G is also a member of IFN system, at least in the resting CD4 T-cells. Given that IFN-a/APOBEC3G pathway has potent anti-HIV-1 capability in resting CD4 T-cells, augmentation of this innate immunity barrier could prevent residual HIV-1 replication in its native reservoir in the post-highly active antiretroviral therapy (HAART) era.